Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected

Rhea-AI Summary

Tevogen Bio Holdings (Nasdaq: TVGN) announced plans to release a comprehensive inventory and valuation of its internally developed assets. CEO Ryan Saadi emphasized that the company is asset-rich with significant intellectual property, drug development platforms, and proprietary AI technology that are fully protected and wholly owned by Tevogen.

The company highlighted that while these intangible assets are not reflected in financial reports due to US GAAP accounting rules, they represent substantial value. With 74% insider ownership and strong lead investor commitment, Tevogen remains focused on advancing its mission in infectious diseases and cancer treatment development.

Positive

• Strong insider ownership at 74% demonstrates management confidence
• Substantial intellectual property portfolio and proprietary AI technology assets
• Assets are fully protected and wholly owned by the company
• Committed lead investor support

Negative

• Intangible assets not reflected in financial reports due to GAAP rules
• Company needs to raise additional capital to execute business plan
• Limited operating history creates execution risk
• Faces significant competition and regulatory challenges

Insights

Biotechnology Business Analyst

Tevogen plans to release internal asset valuation of previously undisclosed intangible assets while affirming 74% insider ownership and full asset protection.

Tevogen is preparing to release a comprehensive inventory and valuation of its internally developed assets that are not currently reflected in its financial reports due to US GAAP accounting rules. This is significant because intangible assets like intellectual property portfolios, drug development platforms, and proprietary AI technology often represent substantial hidden value in biotech companies that doesn't appear on balance sheets.

The announcement comes with several noteworthy data points: the company has 74% insider ownership, suggesting strong internal confidence, and their lead investor remains committed. This high insider ownership percentage is particularly relevant as it indicates management has significant skin in the game and aligns their interests with long-term shareholders.

The timing of this announcement is interesting. Biotech companies typically emphasize their intangible asset valuations when they want to highlight underlying value that isn't reflected in traditional financial metrics or stock price. Given that the release contains no specifics about the actual valuation amounts, investors should wait for the comprehensive inventory before drawing conclusions about the true value proposition.

This move appears designed to reassure shareholders about the company's fundamental value while signaling that management believes the market may not fully appreciate Tevogen's asset base. The emphasis on assets being "fully protected" suggests there may have been concerns about intellectual property security or ownership that the company is trying to address proactively.

WARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), today issued the following statement from Ryan Saadi, M.D., M.P.H., Founder and CEO.

“Tevogen is an asset-rich enterprise, and we plan on sharing a comprehensive inventory of Tevogen’s wholly owned internally developed assets and their standard methodology valuation. These intangible assets are not reflected in financial reports due to US GAAP accounting rules, but they do underscore the magnitude of what we have built in such a short time.

It is important for shareholders to understand that these assets, including our intellectual property portfolio, drug development platforms, and proprietary artificial intelligence technology, are fully protected and wholly owned by Tevogen.

With 74% insider ownership and the commitment of our lead investor, we remain focused on advancing our mission, and we will continue to make strategic decisions in the best interests of our long-term shareholders.”

Forward Looking Statements

This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.

Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K.

You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.

Contacts

Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com

FAQ

What assets does Tevogen Bio (TVGN) plan to disclose in their valuation?

Tevogen plans to disclose their intellectual property portfolio, drug development platforms, and proprietary artificial intelligence technology assets along with their standard methodology valuation.

What is the insider ownership percentage of Tevogen Bio stock?

Tevogen Bio has 74% insider ownership, demonstrating significant management commitment to the company.

Why are Tevogen Bio's intangible assets not shown in financial reports?

The intangible assets are not reflected in financial reports due to US GAAP accounting rules, despite their significant value to the company.

What are the main risks facing Tevogen Bio (TVGN)?

Key risks include the need to raise additional capital, regulatory challenges, competition in the market, and limited operating history.

What therapeutic areas is Tevogen Bio focusing on?

Tevogen Bio is focused on developing treatments for infectious diseases and cancer.